Why Eisai’s Aricept still shapes Alzheimer’s everyday treatment

Aricept from Eisai has been on the market for years, yet in many neurology practices it still sets the tone for how mild to moderate Alzheimer’s is treated. Where the drug convinces, where it is limited, and why it remains a quiet standard.

Reviewed: ad hoc news Classics & Longseller desk. Edited and checked on 2026-06-18, 03:21. Details in the imprint.

Aricept is one of those medicines you almost overlook in a neurologist’s drawer, yet families of Alzheimer’s patients often know the small tablets painfully well. The Alzheimer’s drug from Eisai promises no miracle, just a little more clarity, a few more structured days.

What Aricept actually does

Aricept, the brand name for donepezil, is approved for the symptomatic treatment of mild to severe Alzheimer’s dementia and belongs to the group of acetylcholinesterase inhibitors.

It does not stop the disease, but it aims to slow cognitive decline and help maintain daily functions a bit longer for some patients.

How the drug is taken

In everyday practice, Aricept is usually started at a low daily dose in the evening, then slowly increased if tolerated, because nausea and sleep disturbances can occur particularly at the beginning of therapy.

The small, film-coated tablets are discreet, easy to swallow, and designed for long-term daily use, which matters when routines already feel fragile for patients and caregivers.

Strengths in real-life use

Doctors often report that, in responsive patients, Aricept can stabilize memory, orientation, and ability to cope with simple tasks for several months, sometimes longer, giving families a noticeable breathing space.

For relatives, even small effects can feel big: the grandfather who still recognizes his granddaughter’s voice, or the partner who can safely prepare a simple breakfast for a while longer.

Where Aricept reaches its limits

The flip side is clear expectations management: Aricept does not cure Alzheimer’s, and many patients show only modest improvement or a slowing of decline that is difficult to separate from natural fluctuations.

Side effects such as gastrointestinal complaints, muscle cramps, weight loss, or insomnia can be serious enough in frail elderly patients that doctors need to adjust or discontinue therapy.

Place in a changing treatment landscape

While new Alzheimer’s drugs target amyloid and other disease mechanisms, Aricept remains a reference point in many treatment guidelines as a baseline symptomatic option for suitable patients.

In clinical everyday life, neurologists often combine structured non-pharmacological support with Aricept to keep patients mobile and socially integrated as long as possible.

Company context and listing

For Eisai, Aricept is a classic product that helped establish its neurology franchise and now sits alongside newer dementia candidates in development pipelines. Shares of Eisai Co Ltd (JP3160400002) trade primarily on the Tokyo Stock Exchange in Japanese yen.

Key facts on Aricept

• Product: Aricept (donepezil)
• Manufacturer: Eisai Co Ltd
• Category: Classic/Longseller prescription medicine
• Launch: Mid-1990s, with subsequent global rollouts
• RRP / Price: Varies by dosage and market, often reimbursed in national health systems
• Availability: Widely available by prescription in neurology and psychiatric practices, hospital and retail pharmacies
• Target group: Adults with mild to severe Alzheimer’s dementia under medical supervision
• Highlight / USP: Long-established, once-daily cholinesterase inhibitor with broad clinical experience worldwide

This article was AI-assisted and editorially reviewed. Product information without guarantee; prices and availability may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions involve risks up to total loss.